<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">

    <title type="text">Quorum Consulting News Feed</title>
    <subtitle type="text">15 Latest News Articles</subtitle>
    <link rel="alternate" type="text/html" href="" />
    <link rel="self" type="application/atom+xml" href="http://quorumconsulting.com/feeds/news/" />
    <updated>2011-11-07T19:50:31Z</updated>
    <rights>Copyright (c) 2011, Admin</rights>
    <generator uri="http://www.pmachine.com/" version="1.5.2">ExpressionEngine</generator>
    <id>tag:,2011:11:07</id>


    <entry>
      <title>2011 Journal of American Heart Association</title>
      <link rel="alternate" type="text/html" href="http://quorumconsulting.com/site/2011_journal_of_american_heart_association/" />
      <id>tag:,2011:/1.307</id>
      <published>2011-11-07T19:47:01Z</published>
      <updated>2011-11-07T19:50:31Z</updated>
      <author>
            <name>Admin</name>
            <email>info@quorumconsulting.com</email>
                  </author>

      <category term="Cardiovascular"
        scheme="http://quorumconsulting.com/site/C3/"
        label="Cardiovascular" />
      <category term="Medical Device"
        scheme="http://quorumconsulting.com/site/C18/"
        label="Medical Device" />
      <content type="html"><![CDATA[
        <p>The cost-effectiveness associated with continuous flow LVADs for destination therapy has improved significantly relative to the pulsatile flow devices. This change is explained by significant improvements in survival, functional status and reduction in implantation costs.
</p>
      ]]></content>
    </entry>

    <entry>
      <title>Commercialization of Molecular Diagnostics</title>
      <link rel="alternate" type="text/html" href="http://quorumconsulting.com/site/commercialization_of_molecular_diagnostics/" />
      <id>tag:,2011:/1.302</id>
      <published>2011-08-25T00:43:00Z</published>
      <updated>2011-08-25T00:56:51Z</updated>
      <author>
            <name>Admin</name>
            <email>info@quorumconsulting.com</email>
                  </author>

      <content type="html"><![CDATA[
        <p>The objective of this session is to understand how regulatory, reimbursement, and commercialization activities were developed for a new therapy and a companion diagnostic. Specific milestones and timelines will be discussed so that the audience can benchmark their own experiences and future plans.&nbsp; Next Generation Dx Summit, Washington D.C. August 25, 2011
</p>
      ]]></content>
    </entry>

    <entry>
      <title>Quorum 2011: Journal of Cardiac Surgery</title>
      <link rel="alternate" type="text/html" href="http://quorumconsulting.com/site/quorum_2011_journal_of_cardiac_surgery/" />
      <id>tag:,2011:/1.301</id>
      <published>2011-08-25T00:35:00Z</published>
      <updated>2011-08-25T00:43:06Z</updated>
      <author>
            <name>Admin</name>
            <email>info@quorumconsulting.com</email>
                  </author>

      <content type="html"><![CDATA[
        <p>A recent prospective, randomized controlled trial demonstrated that a continuous flow (CF) left ventricular assist device (LVAD) resulted in improved survival at 12 and 24months compared to a pulsatile-flow (PF) device. The current study examines the hospitalization costs associated with treatment of New York Heart Failure Class IV patients when implanted with a CF LVAD and compares them to previously reported costs of a PF LVAD in the same population. Journal of Cardiac Surgery August 2011
</p>
      ]]></content>
    </entry>

    <entry>
      <title>2011 Clinical Ophthalmology</title>
      <link rel="alternate" type="text/html" href="http://quorumconsulting.com/site/2011_clinical_ophthalmology/" />
      <id>tag:,2011:/1.295</id>
      <published>2011-07-14T17:32:00Z</published>
      <updated>2011-07-14T17:36:32Z</updated>
      <author>
            <name>Admin</name>
            <email>info@quorumconsulting.com</email>
                  </author>

      <content type="html"><![CDATA[
        <p>Clinical Ophthalmology: July 2011;  Evaluation of economic efficiencies in clinical retina practice: activity-based cost analysis and modeling to determine impacts of changes in patient management.<BR>The purpose of this study is to report the use of activity-based cost analysis to identify areas of practice efficiencies and inefficiencies within a large academic retinal center and a small single-specialty group.<BR><a href="http://quorumconsulting.com/docs/f_OPTH-22019-evaluation-of-efficiencies-in-clinical-retina-practice---uti_071111_10518_(2).pdf">2011 Clinical Ophthalmology</a>
</p>
      ]]></content>
    </entry>

    <entry>
      <title>2011 ASCO Annual Meeting</title>
      <link rel="alternate" type="text/html" href="http://quorumconsulting.com/site/2011_asco_annual_meeting/" />
      <id>tag:,2011:/1.293</id>
      <published>2011-05-26T18:01:00Z</published>
      <updated>2011-05-26T18:31:32Z</updated>
      <author>
            <name>Admin</name>
            <email>info@quorumconsulting.com</email>
                  </author>

      <content type="html"><![CDATA[
        <p>2011 ASCO Annual Meeting: Abstract &#8220;Trends in utilization of oncology drugs for Medicare fee-for-service beneficiaries from 2002 through 2009&#8221; is published as part of the 2011 Annual Meeting of the American Society of Clinical Oncology.&nbsp; The abstract is available on <a href="http://abstract.asco.org/AbstView_102_84597.html">www.asco.org</a> and <a href="http://jco.ascopubs.org/">Journal of Clinical Oncology</a><br>
</p>
      ]]></content>
    </entry>

    <entry>
      <title>Article Published: The burden of disease of retinal vein occlusion: review of the literature</title>
      <link rel="alternate" type="text/html" href="http://quorumconsulting.com/site/article_published_the_burden_of_disease_of_retinal_vein_occlusion/" />
      <id>tag:,2011:/1.291</id>
      <published>2011-05-17T22:19:00Z</published>
      <updated>2011-05-17T22:25:13Z</updated>
      <author>
            <name>Admin</name>
            <email>info@quorumconsulting.com</email>
                  </author>

      <content type="html"><![CDATA[
        <p>MARCH 11, 2011:&nbsp; An article entitled &#8220; The burden of disease of retinal vein occlusion: review of the literature”, coauthored by Marianne Laouri, Er Chen, and Mark Looman,  is published in EYE <a href="http://quorumconsulting.com/docs/RVO_Lit_Review_Laouri_2011_Eye.pdf">RVO_Lit_Review_Laouri_2011_Eye.pdf</a>
</p>
      ]]></content>
    </entry>

    <entry>
      <title>BAYBIO ANNUAL CONFERENCE 2011</title>
      <link rel="alternate" type="text/html" href="http://quorumconsulting.com/site/baybio_annual_conference_2011/" />
      <id>tag:,2011:/1.288</id>
      <published>2011-04-15T20:04:00Z</published>
      <updated>2011-04-15T20:13:01Z</updated>
      <author>
            <name>Admin</name>
            <email>info@quorumconsulting.com</email>
                  </author>

      <content type="html"><![CDATA[
        <p>Kuo Bianchini Tong, MS, Founder and CEO, Quorum Consulting, Inc, is a panelist at the 2011 BayBio Annual Conference in Burlingame on April 21st.
<br />
Private and government-sponsored healthcare reimbursement plans are quickly becoming the dominant forces in the healthcare market. The payers have the power of the purse and thus increasingly the power over which products advance to the market and which products are shelved. This is quickly becoming a key financing issue, as buyers of assets want to see the value proposition based on how the product will be reimbursed. A panel of key hospital and healthcare insurance decision makers will provide insight into their decision making process and discuss what both commercial and pre-commercial companies need to factor into their product development plans in order to reach patients and to get reimbursed.
</p>
<p>
<a href="http://www.baybio.org/events/baybio-annual-conference-2011-track-2-regulatory-and-commercialization/#understandingpayers">http://www.baybio.org/events/baybio-annual-conference-2011-track-2-regulatory-and-commercialization/#understandingpayers</a>
</p>
      ]]></content>
    </entry>

    <entry>
      <title>Quorum presents at CBI’s 6th Annual Medical Device and Diagnostics Reimbursement Strategies Forum</title>
      <link rel="alternate" type="text/html" href="http://quorumconsulting.com/site/quorum_presentsat_cbis_6th_annual_forum_on_medical_device_and_diagnostics_r/" />
      <id>tag:,2011:/1.286</id>
      <published>2011-03-01T03:42:00Z</published>
      <updated>2011-03-01T03:58:37Z</updated>
      <author>
            <name>Admin</name>
            <email>info@quorumconsulting.com</email>
                  </author>

      <content type="html"><![CDATA[
        <p>Kuo Bianchini Tong, Founder and CEO and Marianne Laouri, Ph.D., Practice Leader, Health Economics, Outcomes and Analytics at Quorum Consulting, Inc. present on issues surrounding clinical utlity and commercialization at CBI’s 6th Annual Forum on Medical Device and Diagnostics Reimbursement Strategies in San Diego February 23-24, 2011 at The Westin in San Diego, CA.&nbsp;  Copies of presentations from the conference can be found at:
</p>
<p>
<a href="http://www.cbinet.com/compendiums/pc11192">http://www.cbinet.com/compendiums/pc11192</a>
<br />

</p>
      ]]></content>
    </entry>

    <entry>
      <title>Quorum published in the American Journal of Managed Care</title>
      <link rel="alternate" type="text/html" href="http://quorumconsulting.com/site/quorum_published_in_the_american_journal_of_managed_care/" />
      <id>tag:,2010:/1.284</id>
      <published>2010-12-27T18:51:00Z</published>
      <updated>2010-12-27T19:16:14Z</updated>
      <author>
            <name>Admin</name>
            <email>info@quorumconsulting.com</email>
                  </author>

      <content type="html"><![CDATA[
        
      ]]></content>
    </entry>

    <entry>
      <title>Quorum Published in Retinal Physician</title>
      <link rel="alternate" type="text/html" href="http://quorumconsulting.com/site/quorum_published_in_retinal_physician/" />
      <id>tag:,2010:/1.280</id>
      <published>2010-07-30T18:07:00Z</published>
      <updated>2010-07-30T18:44:25Z</updated>
      <author>
            <name>Natalie Jordan</name>
            <email>natalie.jordan@quorumconsulting.com</email>
                  </author>

      <content type="html"><![CDATA[
        
      ]]></content>
    </entry>

    <entry>
      <title>Quorum Published in The American Journal of Orthopedics</title>
      <link rel="alternate" type="text/html" href="http://quorumconsulting.com/site/quorum_published_in_the_american_journal_of_orthopedics/" />
      <id>tag:,2010:/1.278</id>
      <published>2010-07-29T22:31:00Z</published>
      <updated>2010-07-29T22:47:11Z</updated>
      <author>
            <name>Natalie Jordan</name>
            <email>natalie.jordan@quorumconsulting.com</email>
                  </author>

      <content type="html"><![CDATA[
        
      ]]></content>
    </entry>

    <entry>
      <title>Quorum Published in the American Journal of Respiratory and Critical Care Medicine</title>
      <link rel="alternate" type="text/html" href="http://quorumconsulting.com/site/quorum_published_in_the_american_journal_of_respiratory_and_critical_care_m/" />
      <id>tag:,2010:/1.276</id>
      <published>2010-07-26T20:36:01Z</published>
      <updated>2010-07-26T20:53:24Z</updated>
      <author>
            <name>Natalie Jordan</name>
            <email>natalie.jordan@quorumconsulting.com</email>
                  </author>

      <content type="html"><![CDATA[
        
      ]]></content>
    </entry>

    <entry>
      <title>Quorum&#8217;s President Kuo Tong, Key Industry Speaker at BioExec Institute 2010</title>
      <link rel="alternate" type="text/html" href="http://quorumconsulting.com/site/quorums_president_kuo_tong_key_industry_speaker_at_bioexec_institute_2010/" />
      <id>tag:,2010:/1.275</id>
      <published>2010-06-30T17:56:00Z</published>
      <updated>2010-06-30T18:27:53Z</updated>
      <author>
            <name>Natalie Jordan</name>
            <email>natalie.jordan@quorumconsulting.com</email>
                  </author>

      <content type="html"><![CDATA[
        
      ]]></content>
    </entry>

    <entry>
      <title>Quorum&#8217;s President Kuo Tong hosts DxMA Web Cast Session</title>
      <link rel="alternate" type="text/html" href="http://quorumconsulting.com/site/quorums_president_kuo_tong_hosts_dxma_web_cast_session/" />
      <id>tag:,2010:/1.274</id>
      <published>2010-06-09T17:38:00Z</published>
      <updated>2010-06-09T20:22:13Z</updated>
      <author>
            <name>Natalie Jordan</name>
            <email>natalie.jordan@quorumconsulting.com</email>
                  </author>

      <content type="html"><![CDATA[
        
      ]]></content>
    </entry>

    <entry>
      <title>Quorum Published in Current Medical Research &amp;amp; Opinion</title>
      <link rel="alternate" type="text/html" href="http://quorumconsulting.com/site/quorum_published_in_current_medical_research_opinion/" />
      <id>tag:,2010:/1.271</id>
      <published>2010-05-03T21:43:00Z</published>
      <updated>2010-05-03T22:04:20Z</updated>
      <author>
            <name>Natalie Jordan</name>
            <email>natalie.jordan@quorumconsulting.com</email>
                  </author>

      <content type="html"><![CDATA[
        
      ]]></content>
    </entry>


</feed>
